Thrombosis in thalassemia: Why are we so concerned?

Hemoglobin

Volumn 35, Issue 5-6, 2011, Pages 503-510

  Musallam, Khaled M ^a   Taher, Ali T ^a  

^a AMERICAN UNIVERSITY OF BEIRUT   (Lebanon)

Author keywords

Hypercoagulability; Splenectomy; Stroke; Thalassemia; Thromboembolism; Transfusion

Indexed keywords

BIOLOGICAL MARKER; CD63 ANTIGEN; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; FERRITIN; HEMOGLOBIN; INTERCELLULAR ADHESION MOLECULE 1; IRON; PADGEM PROTEIN; PHOSPHOLIPID ANTIBODY; PROSTACYCLIN; THROMBOXANE A2; VASCULAR CELL ADHESION MOLECULE 1; VON WILLEBRAND FACTOR;

BETA THALASSEMIA; BLOOD TRANSFUSION; CELL ADHESION; DISEASE ASSOCIATION; ENDOTHELIUM CELL; ERYTHROCYTE; FERRITIN BLOOD LEVEL; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPERCOAGULABILITY; IN VIVO CULTURE; INCIDENCE; IRON OVERLOAD; LIFESPAN; PRIMARY PREVENTION; PROTEIN EXPRESSION; PULMONARY HYPERTENSION; REVIEW; RISK ASSESSMENT; SPLENECTOMY; THROMBOCYTE ACTIVATION; THROMBOCYTE AGGREGATION; THROMBOCYTE COUNT; THROMBOEMBOLISM; THROMBOPHILIA; TRANSIENT ISCHEMIC ATTACK; WHITE MATTER;

HUMANS; THALASSEMIA; THROMBOPHILIA; THROMBOSIS;

EID: 81055144362     PISSN: 03630269     EISSN: 1532432X     Source Type: Journal    
DOI: 10.3109/03630269.2011.605499     Document Type: Review

References (40)

1. Steinberg MH, Forget BG, Higgs DR, Weatherall DJ. Disorders of hemoglobin: genetics pathophysiology, and clinical management. 2nd ed. Cambridge: Cambridge University Press; 2009.
2. Borgna-Pignatti C, Rugolotto S, De Stefano P, et al. Survival and complications in patients with thalassemia major treated with transfusion and deferoxamine. Haematologica. 2004;89(10): 1187-1193. (Pubitemid 39390442)
3. Taher AT, Musallam KM, Cappellini MD,Weatherall DJ. Optimal management of beta thalassaemia intermedia. Br J Haematol. 2011;152(5):512-523.
4. Taher AT, Musallam KM, Karimi M, et al. Overview on practices in thalassemia intermedia management aiming for lowering complication rates across a region of endemicity: the OPTIMAL CARE study. Blood. 2010;115(10):1886-1892.
5. Cappellini MD, Motta I, Musallam KM, Taher AT. Redefining thalassemia as a hypercoagulable state. Ann N Y Acad Sci. 2010;1202(231-236.
6. Taher AT, Otrock ZK, Uthman I, Cappellini MD. Thalassemia and hypercoagulability. Blood Rev. 2008;22(5):283-292.
7. Winichagoon P, Fucharoen S, Wasi P. Increased circulating platelet aggregates in thalassaemia. Southeast Asian J Trop Med Public Health. 1981;12(4):556-560. (Pubitemid 12084732)
8. Del Principe D, Menichelli A, Di Giulio S, De Matteis W, Cianciulli P, Papa G. PADGEM/GMP-140 expression on platelet membranes from homozygous beta thalassaemic patients. Br J Haematol. 1993;84(1):111-117. (Pubitemid 23158124)
9. Ruf A, Pick M, Deutsch V, et al. In-vivo platelet activation correlates with red cell anionic phospholipid exposure in patients with beta-thalassaemia major. Br J Haematol. 1997;98(1):51-56. (Pubitemid 27348794)
10. Cappellini MD, Grespi E, Cassinerio E, Bignamini D, Fiorelli G. Coagulation and splenectomy: an overview. Ann N Y Acad Sci. 2005;1054(317-324. (Pubitemid 43031039)
11. Atichartakarn V, Angchaisuksiri P, Aryurachai K, Chuncharunee S, Thakkinstian A. In vivo platelet activation and hyperaggregation in hemoglobin E/beta-thalassemia: a consequence of splenectomy. Int J Hematol. 2003;77(3):299-303. (Pubitemid 37121859)
12. Eldor A, Krausz Y, Atlan H, et al. Platelet survival in patients with beta-thalassemia. Am J Hematol. 1989;32(2):94-99. (Pubitemid 19218210)
13. Eldor A, Lellouche F, Goldfarb A, Rachmilewitz EA, Maclouf J. In vivo platelet activation in beta-thalassemia major reflected by increased platelet-thromboxane urinary metabolites. Blood. 1991;77(8):1749-1753.
14. Rund D, Rachmilewitz E. Beta-thalassemia. N Engl J Med. 2005;353(11):1135-1146.
15. Hershko C, Graham G, Bates GW, Rachmilewitz EA. Non-specific serum iron in thalassaemia: an abnormal serum iron fraction of potential toxicity. Br J Haematol. 1978;40(2):255-263. (Pubitemid 9040657)
16. Kuypers FA, de Jong K. The role of phosphatidylserine in recognition and removal of erythrocytes. Cell Mol Biol (Noisy-le-grand). 2004;50(2):147-158.
17. Tavazzi D, Duca L, Graziadei G, Comino A, Fiorelli G, Cappellini MD. Membrane-bound iron contributes to oxidative damage of beta-thalassaemia intermedia erythrocytes. Br J Haematol. 2001;112(1):48-50. (Pubitemid 32151148)
18. Borenstain-Ben Yashar V, Barenholz Y, Hy-Am E, Rachmilewitz EA, Eldor A. Phosphatidylserine in the outer leaflet of red blood cells from beta-thalassemia patients may explain the chronic hypercoagulable state and thrombotic episodes. Am J Hematol. 1993;44(1):63-65. (Pubitemid 23245064)
19. Helley D, Eldor A, Girot R, Ducrocq R, Guillin MC, Bezeaud A. Increased procoagulant activity of red blood cells from patients with homozygous sickle cell disease and beta-thalassemia. Thromb Haemost. 1996;76(3):322-327. (Pubitemid 26373521)
20. Atichartakarn V, Angchaisuksiri P, Aryurachai K, et al. Relationship between hypercoagulable state and erythrocyte phosphatidylserine exposure in splenectomized haemoglobin E/beta-thalassaemic patients. Br J Haematol. 2002;118(3):893-898. (Pubitemid 35007399)
21. Cappellini MD, Robbiolo L, Bottasso BM, Coppola R, Fiorelli G, Mannucci AP. Venous thromboembolism and hypercoagulability in splenectomized patients with thalassaemia intermedia. Br J Haematol. 2000;111(2):467-473. (Pubitemid 32009338)
22. Habib A, Kunzelmann C, Shamseddeen W, Zobairi F, Freyssinet JM, Taher A. Elevated levels of circulating procoagulant microparticles in patients with beta-thalassemia intermedia. Haematologica. 2008;93(6):941-942. (Pubitemid 351821736)
23. Butthep P, Bunyaratvej A, Funahara Y, et al. Alterations in vascular endothelial cell-related plasma proteins in thalassaemic patients and their correlation with clinical symptoms. Thromb Haemost. 1995;74(4):1045-1049.
24. Butthep P, Bunyaratvej A, Funahara Y, et al. Possible evidence of endothelial cell activation and disturbance in thalassemia: an in vitro study. Southeast Asian J Trop Med Public Health. 1997;28 Suppl 3(141-148A.
25. Hovav T, Goldfarb A, Artmann G, Yedgar S, Barshtein G. Enhanced adherence of beta-thalassaemic erythrocytes to endothelial cells. Br J Haematol. 1999;106(1):178-181. (Pubitemid 29343548)
26. Zalloua PA, Shbaklo H, Mourad YA, Koussa S, Taher A. Incidence of thromboembolic events in Lebanese thalassemia intermedia patients. Thromb Haemost. 2003;89(4):767-768. (Pubitemid 36456977)
27. Iolascon A, Giordano P, Storelli S, et al. Thrombophilia in thalassemia major patients: analysis of genetic predisposing factors. Haematologica. 2001;86(10):1112-1113. (Pubitemid 33031884)
28. Borgna Pignatti C, Carnelli V, Caruso V, et al. Thromboembolic events in beta thalassemia major: an Italian multicenter study. Acta Haematol. 1998;99(2):76-79. (Pubitemid 28119099)
29. Zurlo MG, De Stefano P, Borgna-Pignatti C, et al. Survival and causes of death in thalassaemia major. Lancet. 1989;2(8653):27-30. (Pubitemid 19158169)
30. Taher A, Isma'eel H, Mehio G, et al. Prevalence of thromboembolic events among 8,860 patients with thalassaemia major and intermedia in the Mediterranean area and Iran. Thromb Haemost. 2006;96(4):488-491. (Pubitemid 44560684)
31. Manfre L, Giarratano E, Maggio A, Banco A, Vaccaro G, Lagalla R. MR imaging of the brain: findings in asymptomatic patients with thalassemia intermedia and sickle cell-thalassemia disease. AJR Am J Roentgenol. 1999;173(6):1477-1480.
32. Taher AT, Musallam KM, Nasreddine W, Hourani R, Inati A, Beydoun A. Asymptomatic brain magnetic resonance imaging abnormalities in splenectomized adults with thalassemia intermedia. J Thromb Haemost. 2010;8(1):54-59.
33. Karimi M, Bagheri H, Rastgu F, Rachmilewitz EA. Magnetic resonance imaging to determine the incidence of brain ischaemia in patients with beta-thalassaemia intermedia. Thromb Haemost. 2010;103(5):989-993.
34. Taher AT, Musallam KM, El-Beshlawy A, et al. Age-related complications in treatment-naive patients with thalassaemia intermedia. Br J Haematol. 2010;150(4):486-489.
35. Taher AT, Musallam KM, Karimi M, et al. Splenectomy and thrombosis: the case of thalassemia intermedia. J Thromb Haemost. 2010;8(10):2152-2158.
36. Taher A, Hershko C, Cappellini MD. Iron overload in thalassaemia intermedia: reassessment of iron chelation strategies. Br J Haematol. 2009;147(5):634-640.
37. Crary SE, Buchanan GR. Vascular complications after splenectomy for hematologic disorders. Blood. 2009;114(14):2861-2868.
38. Cadili A, de Gara C. Complications of splenectomy. Am J Med. 2008;121(5):371-375. (Pubitemid 351626015)
39. Sumiyoshi A, Thakerngpol K, Sonakul D. Pulmonary microthromboemboli in thalassemic cases. Southeast Asian J Trop Med Public Health. 1992;23 Suppl 2(29-31.
40. Tripodi A, Cappellini MD, Chantarangkul V, et al. Hypercoagulability in splenectomized thalassemic patients detected by whole-blood thromboelastometry, but not by thrombin generation in platelet-poor plasma. Haematologica. 2009;94(11):1520-1527.